CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 86 enrolled
Drug / intervention
VBP15 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02415439
NCT02415439Phase 1Completed

A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

ReveraGen BioPharma, Inc.·interventional·Posted Apr 14, 2015·Updated Mar 10, 2017

In Brief

A Phase 1 clinical trial evaluating VBP15 and Placebo for Healthy. Completed, enrolled 86 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the safety, tolerability, and PK of various increasing single and multiple doses of VBP15 in healthy adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 14, 2015
Enrollment StartJan 1, 2015
Primary CompletionNov 1, 2015
Study CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.2 years ago

Interventions

VBP15drug

Placebodrug